LivaNova PLC faced substantial headwinds in 2025 owing to a large environmental liability tied to legacy SNIA obligations, which heavily impacted net income despite robust operational results. The company demonstrated strong growth in its core Cardiopulmonary and Neuromodulation segments, supported by geographic diversification and durable consumables revenue streams. Aggressive debt reduction efforts markedly improved the capital structure, enabling enhanced liquidity and financial flexibility. Meanwhile, innovation efforts focused on the development of the aura6000 System signal a strategic pivot towards future growth opportunities in implantable neuromodulation therapies.